IP Library › Patent Application 17242937
Patent Application
App. No. 17/242,937

METHODS OF CANCER IMMUNOTHERAPY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/242,937
Abstract

Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells.

Claims (31)

1 . A method of treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of an isolated human pancreatic progenitor cell, wherein the isolated human pancreatic progenitor cell expresses insulin and betatrophin.

2 . The method of claim 1 , wherein the isolated pancreatic progenitor cell further expresses C-peptide.

3 . The method of claim 1 , wherein the isolated pancreatic progenitor cell further expresses Ngn3.

4 . The method of claim 1 , wherein the isolated pancreatic progenitor cell further expresses C-peptide and Ngn3.

5 . The method of claim 1 , wherein the differentiated cell is a progenitor cell.

6 . The method of claim 5 , wherein the differentiated cell is a pancreatic progenitor cell.

7 . The method of claim 1 , wherein the differentiated cell is a pluripotent stem cell.

8 . The method of claim 1 , wherein the differentiated cell is an endodermal, mesodermal, or ectodermal progenitor cell.

9 . The method of claim 1 , wherein the differentiated cell is a definitive endoderm progenitor cell.

10 . The method of claim 1 , wherein the differentiated cell is a pancreatic endoderm progenitor cell.

11 . The method of claim 1 , wherein the differentiated cell is a multipotent progenitor cell or an oligopotent progenitor cell.

12 . The method of claim 1 , wherein the differentiated cell is a monopotent, bipotent, or tripotent progenitor cell.

13 . The method of claim 1 , wherein the differentiated cell is an endocrine, exocrine, or duct progenitor cell.

14 . The method of claim 1 , wherein the differentiated cell is a beta-cell.

15 . The method of claim 1 , wherein the differentiated cell is an insulin-producing cell.

16 . The method of claim 1 , wherein the administering comprises injecting the isolated pancreatic progenitor cell to the human in need thereof.

17 . The method of claim 1 , wherein the administering comprises implanting the isolated pancreatic progenitor cell to the human in need thereof.

18 . The method of claim 1 , wherein the cancer comprises a pancreatic cancer.

19 . The method of claim 1 , wherein the cancer comprises a carcinoma.

20 . The method of claim 1 , wherein the carcinoma comprises an adenocarcinoma or a choriocarcinoma.

21 . An isolated progenitor cell that expresses betatrophin, betatrophin mRNA, C-peptide, insulin, or any combination thereof, wherein the isolated progenitor cell is differentiated from a mammalian trophoblast stem cell.

22 . An isolated pancreatic progenitor cell, wherein the isolated pancreatic progenitor cell expresses one or more transcription factors selected from the group consisting of Foxa2, Pdx1, Ngn3, Ptf1a, and Nkx6.1.

23 . A method of treating a disease in a mammal in a subject in need thereof, the method comprising administering to the subject an isolated progenitor cell.

24 . A method of screening a substance for use in the treatment of a disease, the method comprising:

a) contacting an isolated pancreatic progenitor cell with the substance; and

b) detecting a change in the level of at least one transcript or protein in the isolated pancreatic progenitor cell.

25 . A method of screening a substance for cellular modulation or cellular toxicity of a cell, the method comprising:

a) contacting an isolated pancreatic progenitor cell with the substance;

b) determining a phenotypic or metabolic change in the isolated pancreatic progenitor cell that results from contact with the substance; and

c) correlating the change with cellular modulation.

26 . A method of producing insulin, betatrophin protein, or betatrophin mRNA, the method comprising contacting a mammalian trophoblast stem cell with one or more agents to activate miR-124, thereby producing a progenitor cell that secretes insulin in response to glucose stimulation or producing a progenitor cell that produces betatrophin protein or betatrophin mRNA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2021
From: LEE, JAU-NAN; LEE, TONY TUNG-YIN; LEE, YUTA
To: ACCELERATED BIOSCIENCES CORP.
Reel/Frame 056091/0650 →